An expression signature classifies chemotherapy-resistant pediatric osteosarcoma

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1748-1754

  Mintz, Michelle B ^a,b   Sowers, Rebecca ^e   Brown, Kevin M ^a   Hilmer, Sara C ^c   Mazza, Bethanne ^f   Huvos, Andrew G ^f   Meyers, Paul A ^f   LaFleur, Bonnie ^g   McDonough, Wendy S ^a   Henry, Michael M ^c   Ramsey, Keri E ^a   Antonescu, Cristina R ^f   Chen, Wen ^f   Healey, John H ^f   Daluski, Aaron ^h   Berens, Michael E ^a   MacDonald, Tobey J ^d   Gorlick, Richard ^e   Stephan, Dietrich A ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; CD31 ANTIGEN; DESMOPLAKIN; GENE PRODUCT; LIPOCORTIN 2; OLIGONUCLEOTIDE; OSTEONECTIN; OSTEOPROTEGERIN; PHOSPHOLIPASE A2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CHEMOTHERAPY; CHILDHOOD CANCER; COHORT ANALYSIS; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MICROENVIRONMENT; NECROSIS; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; TUMOR GROWTH; VALIDATION PROCESS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CHILD; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHOTREXATE; MICE; MICE, SCID; NECROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20144387214     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2463     Document Type: Article

References (37)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89.
2. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30.
3. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
4. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106:55-67.
5. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003;25:845-53.
6. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 2003;25:840-1.
7. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-94.
8. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/ MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
10. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-78.
11. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
12. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463-7.
13. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892-8.
14. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277: 24571-8.
15. Takahashi S, Reddy SV, Chirgwin JM, et al. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem 1994; 269:28696-701.
16. 2-mediated bone resorption associated with inflammation. J Exp Med 2003;197:1303-10.
17. 2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 2003;8:710-6.
18. Krieger NS, Bushinsky DA, Frick KK. Cellular mechanisms of bone resorption induced by metabolic acidosis. Semin Dial 2003;16:463-6.
19. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 2003; 300:957-64.
20. Okada Y, Pilbeam C, Raisz L, Tanaka Y. Role of cyclooxygenase-2 in bone resorption. J Uoeh 2003;25: 185-95.
21. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-24.
22. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-65.
23. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-8.
24. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33:216-28.
25. Lawler J, McHenry K, Duquette M, Derick L. Characterization of human thrombospondin-4. J Biol Chem 1995;270:2809-14.
26. Newman PJ, Albelda SM. Cellular and molecular aspects of PECAM-1. Nouv Rev Fr Hematol 1992;34: S9-13.
27. Sharma B, Handler M, Eichstetter I, et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998;102:1599-608.
28. Fisher LW, Heegaard AM, Vetter U et al. Human biglycan gene. Putative promoter, intron-exon junctions, and chromosomal localization. J Biol Chem 1991; 266:14371-7.
29. Girard JP, Springer TA. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 1995;2:113-23.
30. Ruhrberg C, Watt FM. The plakin family: versatile organizers of cytoskeletal architecture. Curr Opin Genet Dev 1997;7:392-7.
31. Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. Embo J 1986;5:1865-75.
32. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004;296: 151-62.
33. Endresen L, Rugstad HE. Protective function of metallothionein against certain anticancer agents. Experientia Suppl 1987;52:595-602.
34. Perez OD, Kinoshita S, Hitoshi Y, et al. Activation of the PKB/AKT pathway by ICAM-2. Immunity 2001;16:51-65.
35. Zhang N, Yeh HJ, Zhong R, Li YS, Deuel TF. A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice. Proc Natl Acad Sci U S A 1999;96:6734-8.
36. Souttou B, Juhl H, Hackenbruck J, et al. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst 1998;90:1468-73.
37. Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 2000;60:5284-8.